BR112017005120A2 - composição, conjugado terapêutico isolado, método para tratar câncer em um paciente necessitando do mesmo, método para induzir anticorpos em um indivíduo, composição farmacêutica e método para induzir anticorpos em um indivíduo - Google Patents
composição, conjugado terapêutico isolado, método para tratar câncer em um paciente necessitando do mesmo, método para induzir anticorpos em um indivíduo, composição farmacêutica e método para induzir anticorpos em um indivíduoInfo
- Publication number
- BR112017005120A2 BR112017005120A2 BR112017005120-6A BR112017005120A BR112017005120A2 BR 112017005120 A2 BR112017005120 A2 BR 112017005120A2 BR 112017005120 A BR112017005120 A BR 112017005120A BR 112017005120 A2 BR112017005120 A2 BR 112017005120A2
- Authority
- BR
- Brazil
- Prior art keywords
- individual
- inducing antibodies
- therapeutic
- composition
- therapeutic conjugate
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000001939 inductive effect Effects 0.000 title 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000003247 decreasing effect Effects 0.000 abstract 2
- 230000003111 delayed effect Effects 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 229940022399 cancer vaccine Drugs 0.000 abstract 1
- 238000009566 cancer vaccine Methods 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001173—Globo-H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
a presente descrição abrange composições imunogênicas/terapêuticas incluindo glicoconjugados globo h ?lkh (obi-822) e/ou adjuvantes terapêuticos (obi-821/bi-834) bem como métodos para fazer e utilizar os mesmos para tratar doenças proliferativas tais como câncer. o conjugado terapêutico inclui um antígeno ligado a um veículo. em particular, o conjugado terapêutico inclui uma porção globo h e uma porção klh e/ou uma subunidade da porção klh derivada, opcionalmente ligada via um ligante. as composições terapêuticas são, em parte, previstas para agir como vacinas de câncer para estimular a capacidade natural do corpo para proteger a si mesmo, através do sistema imune a partir de perigos apresentados por células danificadas ou anormais, tais como células cancerígenas. respostas imunes exemplificativas podem ser caracterizadas pela redução da severidade da doença, incluindo, mas não limitado a, prevenção da doença, retardo do início da doença, diminuição da severidade dos sintomas, diminuição da morbidade e retardo na mortalidade.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050567P | 2014-09-15 | 2014-09-15 | |
| US62/050,567 | 2014-09-15 | ||
| PCT/US2015/050270 WO2016044326A1 (en) | 2014-09-15 | 2015-09-15 | Immunogenic/therapeutic glycoconjugate compositions and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112017005120A2 true BR112017005120A2 (pt) | 2018-01-23 |
| BR112017005120B1 BR112017005120B1 (pt) | 2021-01-05 |
Family
ID=55533765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017005120-6A BR112017005120B1 (pt) | 2014-09-15 | 2015-09-15 | composição |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20160339089A1 (pt) |
| EP (1) | EP3193919B1 (pt) |
| JP (1) | JP6774941B2 (pt) |
| KR (2) | KR102679516B1 (pt) |
| CN (1) | CN107427564A (pt) |
| AR (1) | AR101871A1 (pt) |
| AU (1) | AU2015317889B2 (pt) |
| BR (1) | BR112017005120B1 (pt) |
| CA (1) | CA2961522A1 (pt) |
| CL (1) | CL2017000625A1 (pt) |
| ES (1) | ES2797747T3 (pt) |
| IL (1) | IL251120B (pt) |
| MY (1) | MY188880A (pt) |
| PH (1) | PH12017500478A1 (pt) |
| RU (1) | RU2720295C2 (pt) |
| SG (1) | SG11201702037SA (pt) |
| TW (1) | TWI726850B (pt) |
| WO (1) | WO2016044326A1 (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105764921B (zh) | 2013-09-17 | 2020-06-30 | 台湾浩鼎生技股份有限公司 | 用于诱导免疫反应的糖疫苗组合物及其治疗癌症的用途 |
| EP3344806A4 (en) | 2015-09-04 | 2019-03-20 | OBI Pharma, Inc. | GLYCAN NETWORKS AND METHODS OF USE |
| WO2017172990A1 (en) | 2016-03-29 | 2017-10-05 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| AU2017252128B2 (en) | 2016-04-22 | 2024-06-06 | Obi Pharma, Inc. | Cancer immunotherapy by immune activation or immune modulation via Globo series antigens |
| EP3490592A4 (en) * | 2016-07-27 | 2020-03-25 | OBI Pharma, Inc. | IMMUNOGENIC / THERAPEUTIC GLYCAN COMPOSITIONS AND USES THEREOF |
| TWI786054B (zh) | 2016-07-29 | 2022-12-11 | 台灣浩鼎生技股份有限公司 | 人類抗體、醫藥組合物、及其方法 |
| TWI767959B (zh) | 2016-11-21 | 2022-06-21 | 台灣浩鼎生技股份有限公司 | 共軛生物分子、醫藥組成物及方法 |
| EP3775894B1 (en) * | 2018-05-11 | 2024-04-24 | OBI Pharma, Inc. | Method for predicting human immune response |
| US11203645B2 (en) | 2018-06-27 | 2021-12-21 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6544952B1 (en) * | 1994-03-15 | 2003-04-08 | Sloan-Kettering Institute For Cancer Research | Synthesis of glycoconjugates of the globo-H epitope and uses thereof |
| US7854934B2 (en) * | 1999-08-20 | 2010-12-21 | Sloan-Kettering Institute For Cancer Research | Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof |
| US7824687B2 (en) * | 1999-08-20 | 2010-11-02 | Sloan-Kettering Institute For Cancer Research | Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof |
| CN1543350A (zh) * | 2001-08-14 | 2004-11-03 | 糖半抗原和聚集的蛋白载体的免疫原性结合物 | |
| WO2010005735A2 (en) * | 2008-06-16 | 2010-01-14 | Academia Sinica | Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment |
| KR101677279B1 (ko) * | 2009-06-16 | 2016-11-29 | 아카데미아 시니카 | 신규한 당지질 애주번트를 갖는 ｇｌｏｂｏ ｈ 및 관련 항암 백신 |
| EP2500035A1 (en) * | 2011-03-15 | 2012-09-19 | Icon Genetics GmbH | Pharmaceutical formulation containing immunglobulin |
| EP2941436B1 (en) * | 2013-01-04 | 2020-12-02 | OBI Pharma, Inc. | Vaccines with higher carbohydrate antigen density and novel saponin adjuvant |
| CN105764921B (zh) * | 2013-09-17 | 2020-06-30 | 台湾浩鼎生技股份有限公司 | 用于诱导免疫反应的糖疫苗组合物及其治疗癌症的用途 |
-
2015
- 2015-09-15 RU RU2017112982A patent/RU2720295C2/ru active
- 2015-09-15 EP EP15842660.1A patent/EP3193919B1/en active Active
- 2015-09-15 JP JP2017514552A patent/JP6774941B2/ja active Active
- 2015-09-15 AU AU2015317889A patent/AU2015317889B2/en active Active
- 2015-09-15 KR KR1020177009879A patent/KR102679516B1/ko active IP Right Grant
- 2015-09-15 BR BR112017005120-6A patent/BR112017005120B1/pt active IP Right Grant
- 2015-09-15 KR KR1020237023433A patent/KR102702705B1/ko active IP Right Grant
- 2015-09-15 CA CA2961522A patent/CA2961522A1/en active Pending
- 2015-09-15 AR ARP150102941A patent/AR101871A1/es not_active Application Discontinuation
- 2015-09-15 ES ES15842660T patent/ES2797747T3/es active Active
- 2015-09-15 WO PCT/US2015/050270 patent/WO2016044326A1/en active Application Filing
- 2015-09-15 MY MYPI2017000385A patent/MY188880A/en unknown
- 2015-09-15 TW TW104130500A patent/TWI726850B/zh active
- 2015-09-15 CN CN201580062962.2A patent/CN107427564A/zh active Pending
- 2015-09-15 SG SG11201702037SA patent/SG11201702037SA/en unknown
- 2015-09-15 US US14/855,260 patent/US20160339089A1/en active Pending
-
2017
- 2017-03-13 IL IL251120A patent/IL251120B/en active IP Right Grant
- 2017-03-13 PH PH12017500478A patent/PH12017500478A1/en unknown
- 2017-03-14 CL CL2017000625A patent/CL2017000625A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017005120B1 (pt) | 2021-01-05 |
| EP3193919B1 (en) | 2020-04-08 |
| WO2016044326A1 (en) | 2016-03-24 |
| US20160339089A1 (en) | 2016-11-24 |
| KR102679516B1 (ko) | 2024-07-02 |
| MY188880A (en) | 2022-01-12 |
| KR20170090405A (ko) | 2017-08-07 |
| JP2017532310A (ja) | 2017-11-02 |
| IL251120A0 (en) | 2017-04-30 |
| JP6774941B2 (ja) | 2020-10-28 |
| CN107427564A (zh) | 2017-12-01 |
| EP3193919A4 (en) | 2018-04-18 |
| CA2961522A1 (en) | 2016-03-24 |
| CL2017000625A1 (es) | 2018-02-02 |
| EP3193919A1 (en) | 2017-07-26 |
| ES2797747T3 (es) | 2020-12-03 |
| RU2720295C2 (ru) | 2020-04-28 |
| RU2017112982A (ru) | 2018-10-17 |
| IL251120B (en) | 2021-05-31 |
| TWI726850B (zh) | 2021-05-11 |
| TW201628646A (zh) | 2016-08-16 |
| KR102702705B1 (ko) | 2024-09-04 |
| WO2016044326A9 (en) | 2017-05-11 |
| KR20230109783A (ko) | 2023-07-20 |
| AR101871A1 (es) | 2017-01-18 |
| SG11201702037SA (en) | 2017-04-27 |
| RU2017112982A3 (pt) | 2019-04-24 |
| PH12017500478A1 (en) | 2017-07-10 |
| AU2015317889B2 (en) | 2021-06-03 |
| AU2015317889A1 (en) | 2017-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017005120A2 (pt) | composição, conjugado terapêutico isolado, método para tratar câncer em um paciente necessitando do mesmo, método para induzir anticorpos em um indivíduo, composição farmacêutica e método para induzir anticorpos em um indivíduo | |
| BR112019001656A2 (pt) | composição, composição farmacêutica, vacina, método para induzir anticorpos em um indivíduo, método para tratar câncer em um paciente necessitando do mesmo e método para induzir ou melhorar a reação imune em um indivíduo necessitando do mesmo | |
| BR112015032713A2 (pt) | composto; composição terapêutica; composição farmacêutica; método para tratar o câncer em um paciente em necessidade; e método para induzir anticorpos em um animal ou um humano para a finalidade de criar anticorpos monoclonais para usos terapêuticos ou diagnósticos | |
| MX2018010586A (es) | Nanovacuna de activacion de "sting" para inmunoterapia. | |
| NI202000040A (es) | Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y métodos de uso de estos | |
| PE20191081A1 (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza | |
| EA201791150A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака | |
| BR112017009398A2 (pt) | moléculas de ligação específicas para cd73 e seus usos | |
| MX364689B (es) | Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer. | |
| ZA202206809B (en) | Hiv vaccines comprising one or more population episensus antigens | |
| BRPI0815578B8 (pt) | Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer) | |
| BR112019008844A2 (pt) | conjugado de proteína de polissacarídeo imunogênico compreendendo um polissacarídeo derivado de b. streptococcus gbs | |
| RU2014127714A (ru) | ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile | |
| MX2017005687A (es) | Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia. | |
| RU2018123307A (ru) | Вакцинация с использованием альфа3 домена mica/b для лечения рака | |
| EA202090319A1 (ru) | Пептидные конъюгаты, способ конъюгации и их использование | |
| PH12015502844A1 (en) | Mammalian milk osteopontin for enhancing immune responsiveness | |
| BR112022006177A2 (pt) | Kir3dl3 é um receptor inibidor do sistema imune e do mesmo | |
| BR112017002206A2 (pt) | peptídeo derivado de koc1 e vacina incluindo o mesmo | |
| MX2021001288A (es) | Vacunacion con microvesiculas derivadas de celulas tumorales para tratamiento de cancer. | |
| BR112017002212A2 (pt) | peptídeo derivado de cdca1 e vacina contendo o mesmo | |
| BR112017002193A2 (pt) | peptídeo derivado de urlc10 e vacina contendo o mesmo | |
| BR112022013040A2 (pt) | Vacinas individualizadas para o tratamento e prevenção de câncer | |
| WO2022238381A3 (en) | Immunotherapy constructs for treatment of disease | |
| WO2009117365A3 (en) | Vaccine compositions for inducing immune responses against components of drusen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B65X | Notification of requirement for priority examination of patent application | ||
| B65Y | Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117) | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/09/2015, OBSERVADAS AS CONDICOES LEGAIS. |